Evaluation of microRNA levels in blood plasma as potential predictors of schizophrenia
We will purchase and apply a new technology devised by the company Exiqon (http://www.exiqon.com/) . Data will be subject to rigorous internal tests (replicated samples). Data interpretation will be subject to additional tests that establish limits on the probability that any patterns in the data are present by chance. Our publication record includes advanced RNA assays and makes heavy use of data interpretation tests.